Glaukos' 58% launch-driven surge and what other access routes look like

What happened

Glaukos reported third-quarter revenue of $211.0 million, up 58%. The ophthalmic company attributed the growth to strong uptake of two recently launched products, iDose TR and Epioxa. It raised its 2026 revenue guidance to $775–785 million and issued preliminary 2027 guidance of $1 billion.

Taken at face value, the 2027 figure implies growth of roughly 27–29% over the 2026 guidance range. That is our arithmetic, not a company statement. It would mean the launches are expected to sustain momentum into a second full year, not just produce a one-off bump.

Why it matters for market access

For access teams, the main point is that Glaukos ties its revised outlook to launch uptake rather than to a mature portfolio. A guidance raise of this kind rests on assumptions about adoption, and those depend on coverage, coding and payment conditions. The records do not describe the reimbursement or payer status of iDose TR or Epioxa, so we cannot say how much access conditions helped or what they may do to the 2027 target. That is the gap worth probing when the full filing and any earnings commentary are read.

Glaukos is also a reminder that launch performance is judged against external numbers. Investors now have a $1 billion marker for 2027. Competitors, payers and HTA bodies will read that as a sign of commercial scale, and it may shape how they view volume, budget impact and negotiating leverage. This is an interpretation, not something the company said.

Three other routes to market, same day

Other records published the same day show launches reaching payers in quite different ways.

Replimune says its oncolytic HSV-1 therapy Tudriqev, given with nivolumab for advanced melanoma, became commercially available in early October after accelerated approval. The company reports NCCN listing and emerging payer policies while the confirmatory Phase 3 trial enrols. Accelerated approval gets a product on the market early, but evidence expectations remain open. Payers writing first policies in that window often have to decide how to treat a product whose confirmatory data are still pending. The records do not say what those policies contain.

Amarin's situation is almost the reverse. It posted a slim third-quarter 2026 net profit despite a 20% fall in revenue. Its partner Recordati began non-reimbursed sales of icosapent ethyl (Vazkepa) in Poland, so patients or others pay privately. Selling before reimbursement is a deliberate strategy, but the records give no sales figures for Poland, so its commercial value is unknown. It shows that access can start outside the public system, and also that it may not fully replace it.

In Italy, AIFA revised the Fabhalta monitoring registry for C3 glomerulopathy. It removed a blocking eligibility field, the proteinuria threshold, for patients with recurrent disease after kidney transplant. Registries like this act as gatekeepers: if a mandatory field cannot be completed for a clinical subgroup, prescribing and reimbursement can stall. Removing it is a practical change in who can get the drug through the national system. The records do not state the reason for the revision.

Who is affected

Commercial and market access leads at companies with recent launches are the most directly affected. Glaukos has set a public bar for what a successful launch looks like, and teams working on products of any size may face similar questions about adoption pace and payer policy.

Teams with accelerated-approval products should watch how the early payer policies for Tudriqev develop. Those managing EU rollouts should note the contrast between Poland's private-pay entry and Italy's registry-based controls. HTA and pricing teams in Italy that track registry-managed products should check whether similar eligibility fields in their own portfolios cause unintended exclusions.

What we don't know and what to watch

Several points remain open. The records do not say what drives uptake of iDose TR and Epioxa, how they are reimbursed, or how the 2027 projection is built. They do not give the content of Replimune's payer policies, Amarin's Polish sales, or AIFA's rationale for the registry change.

Watch the following: any detail Glaukos gives on coverage and pricing assumptions behind its 2027 figure; whether payer policies for Tudriqev converge or diverge as the confirmatory trial progresses; whether private-pay launches such as Vazkepa in Poland lead to a reimbursement application; and whether AIFA makes similar registry adjustments for other products.